• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

更新的肺癌分期系统。

Updated lung cancer staging system.

机构信息

Thoracic Surgery Service, Hospital Universitario Mutua de Terrassa, 08221 Terrassa, Barcelona, Spain.

出版信息

Future Oncol. 2009 Dec;5(10):1545-53. doi: 10.2217/fon.09.131.

DOI:10.2217/fon.09.131
PMID:20001795
Abstract

The tumor, node and metastasis classification of malignant tumors is periodically revised. Its seventh edition includes the updated classification for lung cancer, based on the analyses of the International Association for the Study of Lung Cancer international database. It is the largest validation ever carried out to date: 100,869 patients registered in 46 databases from 20 countries. The analysis of this database allowed a detailed study of the impact of tumor size on prognosis, the reclassification of additional tumor nodules, the reclassification of pleural dissemination and the separation of two groups of metastatic disease. These changes led to modifications in stage grouping that better differentiate tumors with different prognosis. This updated classification is also recommended for small-cell lung cancer, and for broncho-pulmonary carcinoids. A new international nodal map with stations and zones, and a histological definition of visceral pleura invasion, have also been proposed.

摘要

肿瘤、淋巴结和转移(TNM)分类系统定期修订。其第七版纳入了基于国际肺癌研究协会(IASLC)国际数据库分析的肺癌更新分类。这是迄今为止最大规模的验证:来自 20 个国家的 46 个数据库共登记了 100869 例患者。该数据库分析使我们能够详细研究肿瘤大小对预后的影响、附加肿瘤结节的重新分类、胸膜播散的重新分类以及转移疾病的两个亚组的分离。这些变化导致了分期分组的修改,从而更好地区分具有不同预后的肿瘤。该更新的分类也推荐用于小细胞肺癌和支气管肺类癌。还提出了新的国际淋巴结图,包括淋巴结站和区,以及内脏胸膜侵犯的组织学定义。

相似文献

1
Updated lung cancer staging system.更新的肺癌分期系统。
Future Oncol. 2009 Dec;5(10):1545-53. doi: 10.2217/fon.09.131.
2
The new tumor, node, and metastasis staging system.新的肿瘤、淋巴结和转移分期系统。
Semin Respir Crit Care Med. 2011 Feb;32(1):44-51. doi: 10.1055/s-0031-1272868. Epub 2011 Apr 15.
3
The revised TNM staging system for lung cancer.修订后的肺癌TNM分期系统。
Ann Thorac Cardiovasc Surg. 2009 Feb;15(1):4-9.
4
An update on lung cancer staging.肺癌分期的最新进展。
Adv Anat Pathol. 2010 Jan;17(1):33-7. doi: 10.1097/PAP.0b013e3181c66f15.
5
The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer.国际肺癌研究协会肺癌分期项目:关于即将出版的(第七版)肺癌肿瘤、淋巴结、转移分类中对小细胞肺癌临床分期的建议。
J Thorac Oncol. 2007 Dec;2(12):1067-77. doi: 10.1097/JTO.0b013e31815bdc0d.
6
The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer.国际肺癌研究协会肺癌分期项目:关于将支气管肺类癌肿瘤纳入即将出版的(第七版)肺癌TNM分类的提议。
J Thorac Oncol. 2008 Nov;3(11):1213-23. doi: 10.1097/JTO.0b013e31818b06e3.
7
Updated staging system for lung cancer.肺癌的更新分期系统。
Surg Oncol Clin N Am. 2011 Oct;20(4):655-66. doi: 10.1016/j.soc.2011.07.005.
8
[The new TNM classification in lung cancer].[肺癌的新TNM分类]
Pneumonol Alergol Pol. 2010;78(6):407-17.
9
Lung cancer staging: pathology issues.肺癌分期:病理学问题。
Semin Diagn Pathol. 2012 Aug;29(3):116-26. doi: 10.1053/j.semdp.2012.06.001.
10
The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer.国际肺癌研究协会肺癌分期项目:关于在即将出版的第七版肺癌TNM分类中制定新的国际淋巴结图谱的提议。
J Thorac Oncol. 2009 May;4(5):568-77. doi: 10.1097/JTO.0b013e3181a0d82e.

引用本文的文献

1
Down-regulation of miR-452 is associated with poor prognosis in the non-small-cell lung cancer.miR-452的下调与非小细胞肺癌的不良预后相关。
J Thorac Dis. 2016 May;8(5):894-900. doi: 10.21037/jtd.2016.03.51.
2
CD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer.CD45RO(+)记忆性T淋巴细胞——鳞状非小细胞肺癌TNM免疫评分的候选标志物
Neoplasia. 2015 Nov;17(11):839-48. doi: 10.1016/j.neo.2015.11.004.
3
Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.
预测肺癌预后:分子时代的肿瘤、淋巴结和转移的演变——挑战与机遇。
Transl Lung Cancer Res. 2015 Aug;4(4):415-23. doi: 10.3978/j.issn.2218-6751.2015.07.11.
4
Stage and tissue-specific prognostic impact of miR-182 in NSCLC.非小细胞肺癌中 miR-182 的分期和组织特异性预后影响。
BMC Cancer. 2014 Feb 27;14:138. doi: 10.1186/1471-2407-14-138.
5
High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome.在淋巴结阳性非小细胞肺癌中,微小RNA-21的高肿瘤细胞表达预示着良好的临床结果。
BMC Clin Pathol. 2014 Feb 13;14(1):9. doi: 10.1186/1472-6890-14-9.
6
Metagenes associated with survival in non-small cell lung cancer.与非小细胞肺癌生存相关的元基因。
Cancer Inform. 2011;10:175-83. doi: 10.4137/CIN.S7135. Epub 2011 Jun 2.
7
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.吉西他滨、卡铂和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的 II 期研究。
J Thorac Oncol. 2010 Nov;5(11):1821-5. doi: 10.1097/JTO.0b013e3181f1d23c.